

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated February 17, 2022.

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on February 17, 2022 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk subsidiary Digital Mind Technology starts Phase 1 development of digital therapeutic platform and is on track for completion in Q2, 2022:

- Phase 1 development of new digital therapeutic platform underway
- Pilot Study in 69 patients completed
- Helping cancer patients live better with pain
- Improved mental health outcomes in pain management.

Item 5. Full Description of Material Change

Vancouver, British Columbia – February 17, 2022 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “**Corporation**” or “**Blackhawk**”) is pleased to announce that its subsidiary, Digital Mind Technology Pty. Ltd. (“**DMT**”) has started its phase 1 development of a digital therapeutic application designed for treating cancer patients experiencing pain and at risk of mental health disorders. DMT expects to complete phase 1 in Q2, 2022,

DMT’s clinical trials in cancer patients aim to develop a mindfulness intervention that is useful in pain management. Pain, endured for any length of time unsustainably can result in low mood and lead to depression, anxiety and other related mental health disorders. The mindfulness intervention will be designed to manage negative patterns of thoughts and behaviours.

With pain being one of the most common symptoms reported by nearly 70% of cancer patients¹, DMT is creating a digital therapeutic application and web platform between patients and clinicians that can be used by patients to more effectively deal with pain.

Cancer pain remains a challenging symptom occurring long after treatment completion, with a prevalence of 20-50% in cancer survivors.² The burden of mental health disorders appearing as a co-morbidity in cancer patients is high with around a quarter of cancer patients experiencing depression³⁻⁵. A cancer diagnosis is life changing and in itself is a source of considerable psychological and emotional distress.

Dr Russell says: *“In our pilot clinical trial in 69 patients, we saw that a digital therapeutic was helpful in treating cancer patients cope with fear of cancer recurrence. We are progressing well with our digital therapeutics platform to help cancer patients cope with pain that will have substantial benefit to mental health and wellbeing”.*

1. Van Den Beuken-Van MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. *Journal of pain and symptom management*. 2016;51(6):1070-1090. e1079.
2. Gallaway MS, Townsend JS, Shelby D, Puckett MC. Peer Reviewed: Pain Among Cancer Survivors. *Preventing Chronic Disease*. 2020;17.
3. Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. *Frontiers in Psychology*. 2021;12(1067).
4. Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. *BMJ*. 2018;361:k1415.
5. Hartung TJ, Brähler E, Faller H, et al. The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. *European Journal of Cancer*. 2017;72:46-53.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, TERP Wholesale LLC, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, Digital Mind Therapeutics and MindBio Therapeutics, as well as a share position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel <https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A>

Please join the conversation on our Blackhawk group supporter’s telegram group at <https://t.me/Blackhawkgrowthcorp> and visit us online at <https://www.blackhawkgrowth.com>.

For further information please contact:

Frederick Pels, Chief Executive Officer
(403)-991-7737

fred@blackhawkgrowth.com

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Not applicable

Item 7. Omitted Information
Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer
Telephone: 403-991-7737

Item 9. Date of Report

February 17, 2022